SCHEMBL3971849

SCHEMBL3971849

CC(=O)c1nnccc1C(F)(F)F

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 1/20 0.36
SSTR4 P31391 1/20 0.36
ATM Q13315 1/20 0.33
DHODH Q02127 1/20 0.32
CNR2 P34972 1/20 0.32
MAOA P21397 1/20 0.32
MAOB P27338 1/20 0.32
PTGS2 P35354 1/20 0.32
EPHX1 P07099 1/20 0.31
KLRK1 P26718 1/20 0.31
MICA Q29983 1/20 0.31
RAET1L Q5VY80 1/20 0.31
HDAC6 Q9UBN7 1/20 0.31
TRPV1 Q8NER1 1/20 0.31
CES2 O00748 2/20 0.31
KMT2A Q03164 2/20 0.31
NPC1 O15118 1/20 0.31
POLB P06746 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31445147 0.83 KMO (0.36) SSTR4CNR2
SCHEMBL16346446 0.81 KMT2A (0.36) SSTR4CNR2MAOBCES2KMT2A
SCHEMBL3971002 0.77 GSK3B (0.42) SSTR4CNR2
SCHEMBL1859913 0.74 NFE2L2 (0.47) SSTR4DHODHCNR2MAOAMAOB
SCHEMBL277947 0.72 SMN1; SMN2 (0.35) PTGS2KMT2A
SCHEMBL30937682 0.72 KCNJ1 (0.40) PTGS2TRPV1KMT2A
SCHEMBL34471563 0.71 KMO (0.35) SSTR4DHODHKLRK1MICARAET1L
SCHEMBL669116 0.70 NOTUM (0.32) SSTR4
SCHEMBL22585349 0.70 NOTUM (0.32) KIF11SSTR4
SCHEMBL16276908 0.70 HSD11B1 (0.37) SSTR4KMT2APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1841430-A4 SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORP (US) 2009-07-29 EP disclosed
US-20080175794-A1 Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues NEUROGEN CORPORATION (US) 2008-07-24 US disclosed
US-20080175794-A1 Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues NEUROGEN CORPORATION (US) 2008-07-24 US disclosed
US-20080175794-A1 Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues NEUROGEN CORPORATION (US) 2008-07-24 US disclosed
EP-1841430-A2 SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2007-10-10 EP disclosed
WO-2006081388-A2 SUBSTITUTED PYRIDAZINYL-AND PYRIMIDINYL-QUINOLIN-4-YLAMINE ANALOGUES NEUROGEN CORPORATION (US) 2006-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080175794-A1 Substituted Pyridazinyl- and Pyrimidinyl-Quinolin-4-Ylamine Analogues PIGS, HRH4, GPR68 KIF11 4721/4885SSTR4 658/4885ATM 3908/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.